New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation
Saved in:
Main Author: | article Editorial |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2015-11-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Online Access: | https://www.rpcardio.online/jour/article/view/332 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of rivaroxaban and apixaban therapy with major ischemic or bleeding events in patients with atrial fibrillation. Retrospective cohort real-world evidence study. Press release
by: article Editorial
Published: (2022-03-01) -
CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01) -
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
by: article Editorial
Published: (2022-03-01) -
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
by: Carlos Rubio-Terrés, et al.
Published: (2016-02-01) -
HOW TO REDUCE GASTROINTESTINAL BLEEDING RISK ON ANTICOAGULATION THERAPY IN NON-VALVULAR ATRIAL FIBRILLATION?
by: E. I. Baranova, et al.
Published: (2017-11-01)